Inavolisib

Chemical structure of Inavolisib

Inavolisib is a small molecule inhibitor that targets the phosphoinositide 3-kinase (PI3K) pathway, which is involved in various cellular functions such as growth, proliferation, and survival. It is primarily being investigated for its potential use in the treatment of certain types of cancer.

Mechanism of Action

Inavolisib functions by selectively inhibiting the PI3K enzyme, particularly the PI3K-alpha isoform. The PI3K pathway is often dysregulated in cancer, leading to uncontrolled cell growth and survival. By inhibiting this pathway, Inavolisib aims to reduce tumor growth and induce apoptosis in cancer cells.

Clinical Development

Inavolisib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with advanced solid tumors, including breast cancer and lung cancer. These trials are assessing the drug's ability to shrink tumors, improve survival rates, and its overall impact on patient quality of life.

Potential Side Effects

As with many targeted cancer therapies, Inavolisib may cause side effects. Commonly reported side effects include nausea, fatigue, and rash. More serious adverse effects could include hyperglycemia and liver toxicity, which require careful monitoring during treatment.

Research and Future Directions

Ongoing research is focused on understanding the full potential of Inavolisib in combination with other therapies, such as chemotherapy and immunotherapy. Researchers are also investigating biomarkers that could predict which patients are most likely to benefit from Inavolisib treatment.

Related Pages

• Phosphoinositide 3-kinase
• Cancer treatment
• Targeted therapy